Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM13OVF)

• Drug Name: REMD 477 Drug Info
• Synonyms: Volagidemab

Indication

Disease Entry	ICD 11	Status	REF
Type-1 diabetes	5A10	Phase 2	[1]
Type 2 diabetes	5A11	Phase 1/2	[2]
Type-2 diabetes	5A11	Phase 1/2	[3]

• Cross-matching ID: TTD Drug ID: DM13OVF

Molecule-Related Drug Atlas

Drug(s) Targeting Glucagon receptor (GCGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucagon recombinant	DMFLUTR	Hypoglycemia	5A41	Approved	[5]
Dasiglucagon	DM74SVE	Hypoglycemia	5A41	Approved	[6]
Retatrutide	DM8WU0Q	Obesity	5B81	Phase 3	[7]
MK-8521	DMVNAYE	Type-2 diabetes	5A11	Phase 2	[8]
LY2944876	DML6XWR	Diabetic complication	5A2Y	Phase 2	[9]
TT-401	DMRQ0SA	Type-2 diabetes	5A11	Phase 2	[8]
LGD-6972	DMPL9KG	Type-2 diabetes	5A11	Phase 2	[10]
PF-06291874	DMN94QM	Type-2 diabetes	5A11	Phase 2	[11]
LY-2409021	DMZOIP4	Type-2 diabetes	5A11	Phase 2	[12]
Efinopegdutide	DMAN2V2	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon receptor (GCGR)	TT9O6WS	GLR_HUMAN	Antagonist	[4]

References

• [1] ClinicalTrials.gov (NCT03117998) Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
• [4] Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.
• [5] Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [7] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [10] Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
• [11] Clinical pipeline report, company report or official report of pfizer.
• [12] Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
• [13] Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.